Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fatty liver linked to Body's own oxalate production in new study

NCT ID NCT06735924

Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how much oxalate the body naturally makes in people with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), a type of fatty liver. Researchers will collect urine samples from 28 adults after they eat a special low-oxalate diet. The goal is to better understand the link between liver health and oxalate, which can affect kidney stone risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 28 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2023

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age \>18 years * History of MASLD, with liver fat content \> 5% * Normal kidney function * Stable medication for at least 1 month for diabetes mellitus if any * Willingess to ingest fixed diets and stop dietary supplements for the study and come to UAB for visits Exclusion Criteria: * Age \< 18 years * Inaccurate 24-hour urine collections * Liver fat content \<5% * Liver cirrhosis * Evidence of other chronic liver disease, viral hepatitis * history of alcoholism within 2 years of enrollment * Contra-indication to Magnetic Resonance Imaging * Chronic kidney disease with estimated Glomerular Filtration rate \< 60 ml/min/1.73m2 * Type 1 Diabetes Mellitus or treatment with insulin * Uncontrolled diabetes * Pregnancy, lactation or intention to be * Uncontrolled hypertension * Use of weight loss medication, SGLT2 inhibitors, GLP-1 receptor agonists, osteoporosis medication, chronic NSAID * History of gastric or intestinal surgery or resection that could potentially alter oxalate absorption * Chronic fat malabsorption * Use of immunosuppressive medications * Known immuno-compromised status * Active malignancy or treatment for malignanacy within the last 12 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASLD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MASLD Metabolic dysfunction-associated steatotic liver disease

Contacts and locations

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.